Abstract
Background The global estimated prevalence of long COVID-19 is 43%, and the most common symptoms found globally are fatigue, confusion, or lack of confusion, and dyspnea, with prevalence rates of 23%, 14%, and 13%, respectively. However, long COVID still lacks an overall review in African populations. The aim of this review was to determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms.
Methods A systematic review of long COVID in African populations was conducted. The random effects model was used to calculate the pooled prevalence rates (95% CI). If the results could not be pooled, a narrative synthesis was performed.
Results We included 14 studies from 7 African countries, totaling 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Long COVID had a pooled prevalence of 41% [26%-56%]. Fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms, with prevalence rates (95% CI) of 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively. Long COVID was associated with advanced age, being female, more than three long COVID symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness (P ≤0.05). According to our review, high micro clot and platelet poor plasma (PPP) viscosity explain the pathophysiology of long COVID.
Conclusion Long COVID prevalence in Africa was comparable to the global prevalence. However, the prevalence of the most common symptoms was higher in Africa. Comorbidities associated with long COVID may lead to additional complications in African populations due to hypercoagulation and thrombosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
6. Abbreviations
- -2AP
- -2 antiplasmin
- ACE2
- Angiotensin-Converting Enzyme 2
- AIDS
- acquired immune deficiency syndrome
- ARDS
- acute respiratory distress syndrome
- BMI
- body mass index
- CDC
- Centers for Disease Control and Prevention
- CCS
- Chronic COVID syndrome
- CFS
- chronic fatigue syndrome
- COPD
- Chronic obstructive pulmonary disease
- COVID-19
- Coronavirus disease 2019
- E-selectin
- endothelial-leukocyte adhesion molecule 1
- GORD
- Gastroesophageal reflux disease
- HIV
- human immunodeficiency virus
- HLA
- human leukocyte antigen
- ICU
- intensive care unit
- MIS-A
- multi-system inflammatory syndrome in adults
- MIS
- multisystem inflammatory syndrome
- NICE
- National Institute for Health and Care Excellence
- PASC
- Post-Acute Sequelae of SARS-CoV-2
- PECAM-1
- platelet endothelial cell adhesion molecule-1
- PLWH
- persons living with HIV
- PF4
- platelet factor 4
- PPP
- platelet poor plasma
- RNA
- ribonucleic acid
- RT-PCR
- Reverse transcription polymerase chain reaction
- SAA
- serum Amyloid A
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- TB
- tuberculosis
- UN
- United Nations
- VWF
- Von Willebrand Factor
- WHO
- World Health Organization